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Abstract
Background: Uganda has a long history of health research, but still faces critical health problems. It has made a
number of recent moves towards building science and technology capacity which could have an impact on local
health, if innovation can be fostered and harnessed.
Methods: Qualitative case study research methodology was used. Data were collected through reviews of
academic literature and policy documents and through open-ended, face-to-face interviews with 30 people from
across the science-based health innovation system, including government officials, researchers in research institutes
and universities, entrepreneurs, international donors, and non-governmental organization representatives.
Results: Uganda has a range of institutions influencing science-based health innovation, with varying degrees of
success. However, the country still lacks a coherent mechanism for effectively coordinating STI policy among all the
stakeholders. Classified as a least developed country, Uganda has opted for exemptions from the TRIPS intellectual
property protection regime that include permitting parallel importation and providing for compulsory licenses for
pharmaceuticals. Uganda is unique in Africa in taking part in the Millennium Science Initiative (MSI), an ambitious
though early-stage $30m project, funded jointly by the World Bank and Government of Uganda, to build science
capacity and encourage entrepreneurship through funding industry-research collaboration. Two universities – Makerere
and Mbarara – stand out in terms of health research, though as yet technology development and commercialization is
weak. Uganda has several incubators which are producing low-tech products, and is beginning to move into higher-
tech ones like diagnostics. Its pharmaceutical industry has started to create partnerships which encourage innovation.
Conclusions: Science-based health product innovation is in its early stages in Uganda, as are policies for guiding
its development. Nevertheless, there is political will for the development of STI in Uganda, demonstrated through
personal initiatives of the President and the government’s willingness to invest heavily for the long term in support
of STI through the Millennium Science Initiative. Activities to support technology transfer and private-public
collaboration have been put in motion; these need to be monitored, coordinated, and learned from. In the private
sector, there are examples of incremental innovation to address neglected diseases driven by entrepreneurial
individuals and South-South collaboration. Lessons can be learned from their experience that will help support
Ugandan health innovation.
Background
Uganda is a landlocked country in East Africa with a
population of roughly 32 million [1]. After many years
of political and economic instability, Yoweri Museveni
became president in 1986 and began initiatives to
reform the economy and rehabilitate the educational
system, providing the foundation for the country’sc u r -
rent economic development. Predominantly agricultural,
the economy has been growing steadily over the past
five years. In 2009, the country’s GDP was $15.7 billion
USD, and had been growing at over 6% annually for sev-
eral years [2]. The service sector accounted for 52.8% of
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and 18.2% respectively [1].
Today the Ugandan government recognizes the need
to use science and technology (S&T) as a means to
achieve and maintain favourable socio-economic condi-
tions for its population. It is investing in science educa-
tion, and in 2006 began the $30m Millennium Science
Initiative, a program to help improve human resources
in S&T and to increase productivity in industrial, agri-
cultural and other sectors using scientific tools and
knowledge. Total government R&D spending nearly
tripled from Uganda Shillings 31 billion ($19 million
USD) in 2003/04 to approximately Uganda Shillings 82
billion ($47 million USD) in 2007/08, which accounts
for about 0.4% of GDP in 2007/08 [3].
However, despite the improvement of some socio-
economic indicators, Uganda is still ranked 156
th on the
Human Development Index [4]. In 2008, life expectancy
at birth was 53 years of age [2]. In common with other
sub-Saharan African countries, health status remains
poor. In 2002, HIV/AIDS, the largest disease killer,
accounted for 25% of all deaths in the country followed
by malaria and respiratory infections at 11% each, and
tuberculosis at 4% [5]. Health expenditure by the gov-
ernment in 2007 stood at 2.1% of GDP and 27.9% of
total public expenditure. However, with the current
population size, the per capita public expenditure is
only US$18. As a result, figures for 2007 show that 51%
of health expenditure was private and out of pocket [6].
In this paper we present research on science-based
health innovation in Uganda, including biotechnology.
By science-based health innovation, we mean technolo-
gical innovation across a spectrum of sophistication,
from vaccines, pharmaceuticals, and medical devices to
some plant medicines where attempts to scientifically
standardize or characterize medicines have been made.
We take a broad definition of innovation as not only
new-to-the-world innovation, but also the diffusion,
adaptation and use of technologies. We use the OECD
definition of biotechnology: ‘the application of science
and technology to living organisms, as well as the parts,
products and models thereof, to alter living or non-
living materials for the production of knowledge, goods
and services’ [7].
The purpose of this paper is to describe and analyze
science-based health innovation using an innovation sys-
tem framework, which takes into account the wide vari-
ety of stakeholders who contribute to the innovation
process and emphasizes the dynamic interaction and
knowledge flow between them [8]. The study was
undertaken at the invitation of the Vice President of
Uganda, Professor Gilbert Bukenya. As far as the
authors are aware, this is the first study of its kind on
Uganda, with its emphasis on commercialization and
understanding how knowledge translation happens in
the area of health product development.
Methods
A case study research methodology was used in this
study [9]. Data was collected through reviews of aca-
demic literature and policy documents and through
open-ended, face-to-face interviews in Uganda. Intervie-
wees were identified through purposive and snowball
sampling; we interviewed 30 people from across the
science-based health innovation system, including gov-
ernment officials (n=8), researchers (n=13), private sec-
tor representatives (n=5), international donors (n=2) and
non-governmental organization representatives (n=2) in
February 2009. Since our initial research visits we have
continued to engage stakeholders to address key chal-
lenges we identified, as we will discuss toward the end
of the paper.
A l lq u o t e sa r ef r o mt h ei n t e r v i e w su n l e s sn o t e d ,a n d
with permission. This study was approved by the Office
of Research Ethics of the University of Toronto.
Results and discussion
In the following sections, we describe and discuss Uganda’s
science-based health innovation system.
Government
At the government level, Science Technology and
Innovation (STI) forms part of a number of different
sector-based policies in Uganda. For example, the
National Agricultural Research Policy of 2004 provides
direction for agricultural research including biotechnol-
ogy [10], and the National Industrialization Policy
articulates the use of applied science research to develop
Uganda’s infant industries [11]. In turn, these sector-
based polices draw their priorities from national devel-
opment policies such as the Poverty Eradication Action
Plan (PEAP), the country’s strategic development plan
guiding the formulation of government policy [12]. Each
sector-based policy is managed by the relevant Ministry
with apparently little coordination.
In the absence of a Ministry with responsibility for
STI, the Uganda National Council for Science and
Technology (UNCST), which sits within the Ministry for
Finance, Planning, and Economic Development, is
responsible for developing and advising the government
on STI –particularly on integrating STI into the national
development priorities, and for coordinating science
research and development throughout the country.
UNCST’s priorities include improved agricultural pro-
ductivity and human health. The Council has a Biotech-
nology Desk which, together with the National Biosafety
Committee, is responsible for safe application of bio-
technology. The National Biosafety Committee, which
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relevant ministries, farmers’ organizations and the
private sector, drafted the National Biotechnology and
Biosafety Bill which was approved by the Cabinet in
April 2008. The objective of the Biotechnology/Biosafety
Policy is to provide guidance on the development and
application of biotechnology in Uganda; it aims to pro-
vide a regulatory and institutional framework for safe
research and application of the technology. While this
policy was formulated to support primarily agricultural
biotechnology, these same institutions can also be used
to support the development of health biotechnology.
T h e r ei se v i d e n c et h a tU N C S Th a sm a d ec o n s i d e r a b l e
efforts to coordinate efforts and policies among different
institutions and has had some success; however, it
remains limited by understaffing and its lack of status as
a full Ministry.
The lack of a consolidated STI policy was considered
by interviewees to be very problematic. From 1998, vary-
ing drafts of a national Science & Technology Bill have
been brought forward to the Ugandan Cabinet but
never fully adopted by government. In May 2009,
Cabinet approved the latest draft of a Science, Technol-
ogy and Innovation Bill, which was then to be debated
in Parliament after revisions in the Attorney-General’s
Office. If passed, it will be the first such S&T policy in
Uganda that has gone through parliament [13]. Intervie-
wees saw a need for such a policy framework, and
expressed frustration at the lack of strong policy gui-
dance to support their efforts.
All new drugs, vaccines, medical devices and diagnos-
tics must be registered with the National Drug Author-
ity (NDA), Uganda’s drug regulation agency, before they
are licensed for use in the country. The NDA also per-
forms Good Manufacturing Practice (GMP) audits of
domestic and foreign manufacturers who seek to sell
their products in the country. While the NDA was rela-
tively well-regarded by interviewees, it faces institutional,
human resources and funding challenges which are lim-
iting its ability to work effectively. Funding from its
responsible parent ministry, the Ministry of Health, was
said to be irregular; the pressure to generate internal
funds has led to charging manufacturers for regulatory
checks, raising questions of potential conflicts of inter-
est. Ability to regulate unfamiliar products is also a chal-
lenge: one interviewee cited the ‘huge problem in getting
the NDA to recognize what GMP was in relation to
diagnostics’. Another cited the lack of expertise to prop-
erly regulate health products as the “biggest frustration”.
He suggested that “…the regulatory agency needs to be
strengthened to allow them to do their regulating.”
Guidelines to facilitate the task of regulating, which are
based on WHO Best Practices and modified after dis-
cussions with local scientists and other stakeholders,
remain in draft form awaiting gazetting, the last stage
before they can become legal documents.
The framework to protect intellectual property in
Uganda is through TRIPS (Trade-Related aspects of
Intellectual Property Rights), which Uganda is subject to
as a member of the World Trade Organization (WTO).
Under TRIPS, Uganda is classified as a least developed
country (LDC) and is therefore exempted until July
2016 from meeting certain obligations to implement the
provisions. In moving towards TRIPS compliance, the
Uganda Law Reform Commission was established to
review laws and determine what was needed for compli-
ance by 2016. As a result, bills like the Patents Amend-
ment Bill (drafted 2000) and the Industrial Property Bill
(drafted 2001), both of which make changes to the cur-
rent patent legislation, have been drafted and are await-
ing discussion in parliament. As an LDC, Uganda has
opted for exemptions including permitting parallel
importation and providing for compulsory licenses.
Patent applications in Uganda are submitted through
the African Intellectual Property Organization (ARIPO),
an organization based in Zimbabwe established to pool
the financial and human resources of its member coun-
tries in industrial property matters. Once approved by
ARIPO, the patent is registered at the Registrar-Gener-
al’s Office in the Ministry of Justice in Uganda; no
examination takes place at the national level [14]. How-
ever, no locally-generated patents could be found in the
health sector, and in general attitudes to patenting were
ambivalent. One interviewee said ‘Id o n ’tt h i n ki n
Uganda we are practicing it…Id o n ’tk n o ww h e t h e rw e
have any institution for registering IP’.
Traditional medicine plays an important role in the
healthcare system of Uganda, and more than 60% of the
population depends on it due to low costs, easy access
and cultural acceptance [15]. In 1999, a draft Traditional
and Complementary Medicine Bill was presented to the
Parliament; as of 2009, the Bill still had not passed and
no policy developed for a strategic framework for tradi-
tional medicine. The Ministry of Health does however
include traditional healers in its description of the pri-
vate health sector in Uganda [16].
In the 2007/08 fiscal year, total R&D spending in the
country (public and private sector) was ~0.4% of GDP
and 1.82% of government expenditure [3]. This amount
includes government spending of US$18 million, and
direct donor contribution of US$22 million. However, as
part of Uganda’sn a t i o n a lb u d g e ti sf i n a n c e db yd o n o r s ,
in reality the total donor contribution to R&D is higher.
Of the total R&D amount, US$ 10.2 million was spent
in Medical and Health Sciences R&D which amounts to
25% of total R&D spending.
Two interesting initiatives designed to bridge the gap
between research and industrial application are the
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Support to Scientists Fund. The MSI is a competitive
scheme funded by the World Bank (US$30 million as a
loan to the country on credit terms) and the Ugandan
government (US$3.35 million). Administered by
UNCST, MSI was started in the fiscal year 2006/07 for
an initial four year period. MSI was originally envisaged
as a biotechnology-specific funding initiative in four
African countries (Cameroon, Bostwana, Namibia,
Uganda). However, after extended discussions between
the World Bank and the governments, the initiative was
established only in Uganda and as a multi-science inter-
disciplinary initiative [17]. MSI has been divided into
three categories or Windows. The first two, Windows A
and B, are committed to institutional capacity building
and research: Window A is grant funding for research
teams and Window B provides funding to improve and/
or create undergraduate programs in basic science and
engineering. Grants in these categories have ranged
from US$ 100,000 to US$ 800,000.
The third category in the MSI competitive grant, Pri-
vate Sector Cooperation (or Window C), is a fund that
aims to bridge the industry-research divide by provid-
ing monetary incentives for the two groups to collabo-
rate. Two avenues exist for collaboration within this
Window: Technology Platforms allow firms to identify
a pressing technology problem and collaborate with
researchers to address this problem, while Technology
Internships provide funds for science and engineering
students to formally intern at a firm in order to
acquire hands-on experience in firm-level activities.
Within the Technology Platforms, two stages of fund-
ing exist. The first stage, which has 10 two-year grants
of US$50,000 each, enables firms and researchers to
scout for possible technologies to address the problem.
Once completed, the project team can apply for stage
2 funding (4 two-year grants of US$150,000) to pursue
the research and adaptation needed. Between 2007 and
early 2009, the Council had received about 45-50 pro-
posals, of which four met the criteria and were funded
for the stage 1 phase. A representative from UNCST
highlighted that, despite being a competitive grant
from across the private and public sectors, ‘our initial
focus was to build national capacity, so there is a bias
towards collaboration and team building rather than
just an individual saying ‘I have an exciting innovation
here’.
None of the four were in health or biotechnology;
however the existence of the Window C fund indicates
that opportunities exist for collaboration between firms
and researchers in health and biotechnology. As a new
and innovative initiative its progress should be moni-
tored and evaluated to help learn lessons on how to
support practical innovation activities.
The Presidential Support to Scientists Fund is the
other government funding support for commercializa-
tion. Established in the fiscal year 2006/07 at the request
of President Museveni, this fund provides scientists with
support to take to market ideas that could be commer-
cialized in the near term. Thus far, the Fund, with an
annual budget of US$ 4.2 million [18], has supported
five scientists to develop their innovations through proof
of concept. All supported projects are food-related, such
as fresh vacuum-packed green bananas which keep for
one month (product samples have been sent to UK and
Dubai). One of the projects, the production of a wine
made from an indigenous plant “Murondo,” has also
generated a patent. Although these are micro-scale pro-
jects, they indicate that entrepreneurialism can be sti-
mulated, and that such initiatives may be candidates for
scaling up. An understanding of the dynamics of innova-
tion in these cases could help similar health-related
initiatives.
Finally, to support the use of applied research and
development in industry, the Ugandan government
established the semi-autonomous government agency
Uganda Industrial Research Institute (UIRI); UIRI was
established in 1994 through an interest-free loan pro-
vided by the Chinese government. In 2003, a new direc-
tor, Dr Charles Kwesiga, was appointed, and since then
UIRI has grown. Of note is an incubator program which
began in 2004 and provides support to small entrepre-
neurs. UIRI is currently incubating about eight projects
in-house. Most of them are food-related and concerned
with improving processes of manufacturing. Only one of
them is health related (in animal health): a vaccine pro-
duction laboratory which was scheduled to begin in
mid-2009 production of a vaccine for highly contagious
viral poultry disease called Newcastle disease, based on
a heat-stable vaccine accessed through an Australian
collaborator. UIRI networks with universities and with
UNCST, though linkages are not yet strong – as one
interviewee put it, ‘it’s a shaky bridge’.
Research institutes and universities
Capacity to recruit and train science graduate students
is essential to provide the human resources required for
building up the health sector. Three of Uganda’s univer-
sities provide graduate training in science and technol-
ogy: Makerere University, Mbarara University of Science
and Technology, and Kyambogo University of Science
and Technology, all of which are public universities.
Graduate training in Health Sciences is concentrated at
Makerere University’s College of Health Sciences
(15 Masters programs and 15 PhD programs) and Mbar-
ara University of Science and Technology Faculty of
Medicine (9 Master’s programs and 2 PhD programs).
Kyambogo has no Health Science programs but has 1
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and Kyambogo are relatively new universities estab-
lished, in 1989 and 2001 respectively, to meet the rising
demand for scientists. Additionally, 90% of the govern-
ment scholarships in public universities are geared
towards scientists, with the remaining 10% reserved for
students in the Arts [3]. Despite these efforts at increas-
ing science capacity, interviewees indicated that lack of
human capacity is a major impediment to innovation in
the country.
Health research also takes place in public sector health
research institutes. To coordinate all public sector
health research in the country, the Uganda National
Health Research Organization (UNHRO) was set up to
act as Uganda’s equivalent of the US National Institutes
of Health (NIH) – coordinating health research and
receiving government and donor funds targeted at
health research, thus promoting accountability for, and
effective use of, funds. The government enacted
UNHRO in May 2009, bringing the activities of the
eight government health research institutes under one
umbrella. (These eight institutes were the Uganda Virus
Research Institute, Uganda Cancer Institute, Uganda
Tuberculosis Investigation Centre, Natural Chemothera-
peutics Lab, Central Public Health Laboratory, Uganda
Trypanosomiasis Research Organization, Uganda Joint
Clinical Research Centre, and Uganda Heart Institute).
This is a promising development for Uganda.
Makerere University
Uganda’s largest and oldest university, Makerere Univer-
sity has approximately 30,000 undergraduate and 7,000
graduate students, and was the only public university
until 1990 [14]. Established as a technical school in
1922, it achieved university college status first as part of
the University of London in 1949, then as part of the
University of East Africa in 1963. Makerere traditionally
has specialized in medical and agricultural teaching and
research [16]. A number of departments are involved in
biotechnology research, including the College of Health
Sciences and the Faculty of Veterinary Medicine within
the Department of Parasitology and Microbiology. The
College of Health Sciences has multiple international
collaborations with institutes such as Johns Hopkins
University (US), Yale University (US), Walter Reed
Army Medical Centre (US) and Karolinska Institute
(Sweden); these collaborations deepen its health research
activities, particularly in HIV/AIDS and malaria.
In 2008 Makerere’s governing body approved an IP
management policy to encourage its academics to com-
mercialize their research, and a tech transfer office has
been established in the university. So far there are no
examples of health research commercialization for local
application. One interviewee explained this by character-
izing the type of research occurring as ‘operational
research’, and maintained that donors, who fund the
majority of health research, ‘are not interested in R&D
in Uganda’.
An interesting initiative that has generated technology
transfer, albeit of low-tech products, is the Innovations
at Makerere (or I@Mak) program, funded by the Rocke-
feller Foundation. Some products that have been trans-
f e r r e dt ot h ec o m m u n i t yi n c l u d eaf u e l - f r e ei n c i n e r a t o r
that uses the gas byproduct of the burning waste to fuel
the incinerator, and sanitary pads made from local
plants that cost a fraction of the price of conventional
pads. The incinerator has been taken up by the United
Nations High Commission on Refugees, to be installed
in refugee camps in the country, while the pads have
been adopted by the United Nations Children’s Fund for
distribution to schoolgirls to reduce interruptions to
their daily attendance at school. Such initiatives illus-
trate a general decentralization process that seems to be
occurring in Uganda, with universities becoming more
linked into local civic and governance needs.
Of particular note is the Makerere University Private
Sector Forum (MUPSF) which was established to create
linkages between industry and the university. Specifi-
cally, the aim is to bring private sector leaders closer to
the university in order to match industry need and uni-
versity research and training. A major part of this initia-
tive has been the establishment of honorary
professorship positions at the University which have
been awarded to five eminent private sector leaders. The
initiative has been well received by the private sector
leaders; one leader has proposed the establishment and
funding of university chairs across various disciplines,
and another leader has proposed establishing a research
think-tank on economic policy. The Forum is currently
focused on tailoring the university curriculum to meet
the skills needs of the private sector, and it is just begin-
ning to initiate dialogue among its members about
industry-research linkages for commercialization.
Natural Chemotherapeutics Laboratories
Many interviewees identified traditional medicine as an
area to focus on with respect to deepening Uganda’s
research expertise. The Natural Chemotherapeutics
Laboratory is an existing research facility under the
Ministry of Health, which is responsible for providing
science-based evidence to claims of efficacy of tradi-
tional medicine. The lab has a range of products in
development, or in some cases being sold in the market.
However no full-scale efficacy trials have been done and
manufacturing capacity is limited.
To date, no firms have collaborated with the Labora-
tory. The low appreciation of commercialization is one
reason why. One researcher commented that he recog-
nized that he ‘n e e d st oo v e r c o m es o m ei n e r t i a ’,w h i c h
reflects hesitation to invest resources and time into the
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and unfamiliar. Another researcher commented that
local researchers tend to ‘go where things are moving
faster’ and prioritize projects that are well-funded,
mostly international collaborations, while their own
local research stagnates.
With the wealth of ongoing health research in the
country, the two main challenges our study identified in
Uganda’s research environment are the uncoordinated
nature of the research efforts and the lack of human
resources to carry out the research and development.
Coordination has been difficult as the delay in enacting
UNHRO created a vacuum in health research manage-
ment and coordination. The lack of human resources is
felt by all research institutes as the numbers graduating
from the university programs are not enough to meet
the demand for well-trained researchers.
Table 1 shows the products and processes being
developed in Uganda’s research institutes.
Private sector
T h ep r e s e n c eo fap h a r m a c e u t i c a li n d u s t r yi nac o u n t r y
is important for science-based health research and
development to facilitate the final stage of the innova-
tion cycle, especially for pharmaceutical products like
drugs and vaccines. In Uganda, the pharmaceutical
industry is small and focused on generics, manufactur-
i n g1 0 %o ft h ed r u gp r o d u c t sc o n s u m e di nU g a n d a ,
with 90% imported mainly from India and China [19].
The Uganda National Drug Authority lists ten pharma-
ceutical firms in the country approved to manufacture
generics. Some of these are building capacity in pharma-
ceutical manufacturing through South-South partnership
agreements, and moving into areas of incremental
innovation.
For example, Quality Chemicals, a domestic pharma-
ceutical firm, is the first firm to manufacture anti-
retrovirals (ARVs) in Uganda. In 2005, Quality Chemi-
cals established a partnership to produce ARVs with
Indian generics manufacturer Cipla, where Quality Che-
micals imports the active pharmaceutical ingredient
from the Indian company. Cipla’s decision to partner
with Quality Chemicals is partly due to the fact that
Uganda’s IP regime takes advantage of a WTO waiver
allowing poor countries to import generics of patented
medicines without violating patent rights [20,21]. As of
February 2009, the factory had scaled up to full com-
mercial production, and since then has been manufac-
turing the triple-therapy generic ARV DUOVIR-N,
which is a combination of three drugs in one tablet
(Zidovudine, Lamivudine and Nevirapine). Quality Che-
micals is also the first manufacturer in the country to
achieve World Health Organization (WHO) GMP certi-
fication to enable them to be considered in international
tenders.
The largest drug manufacturer in Uganda is Kampala
Pharmaceutical Industries (KPI), owned by the Aga
Khan Development Network, a collection of develop-
ment groups active primarily in Asia and Africa. and
with a mandate that includes supporting local industry
development. KPI’s best known example of incremental
innovation is Homapak, a chloroquine combination
therapy developed as part of an integrated approach to
address malaria in infants called “home-based manage-
ment of fever”. Developed in partnership with the WHO
and the Ministry of Health, homebased management
involved both incremental technological innovation in
the form of Homapack but also the social intervention
of training drug distrubutors in local communities to
treat children. This approach, was widely seen as an
effective means to reducing infant mortality rates from
malaria, and WHO recommended Homapak as the stan-
dard national treatment until 2006 when the world stan-
dard of malaria treatment changed to artemisinin.
Table 1 Products and Processes being developed in Uganda’s research institutes
Product Health Area Institute /
Organization
Description
Aloe vera Topical – for
skin conditions
Makerere University Traditional medicine. Available for use.
Aloe vera Topical – for
wounds
Natural
Chemotherapeutics
Laboratory
Traditional medicine – is said to promote synthesis of collagen.
Available for use.
Avocine (avocado seed powder) HIV/AIDS
Malaria
Uganda Industrial
Research Institute
Traditional medicine –A nutritional supplement. Sold on the
market
Artemisia annua/elephant grass Malaria Natural
Chemotherapeutics
Laboratory
Traditional medicine - beverage preparation for treatment. In
clinical trials
Peptide-based malaria vaccine Malaria Makerere University Proof of concept successful but stagnated at next stage of
development.
Rapid test for detection of multi-drug
resistant tuberculosis (MDR-TB)
Tuberculosis Makerere University Enzyme-linked immunosorbent assay (ELISA) test for identifying
MDR-TB in sputum; no incentive for commercialization
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ing artemisinin combination therapies for malaria treat-
ment through another technology transfer agreement
with Cipla.
One of the main challenges found for firms was access
to markets, with firms looking beyond the Ugandan
market into the Democratic Republic of Congo (DRC),
Southern Sudan, and Rwanda. However, infrastructure
and fragmented delivery networks pose considerable
problems both domestically and across countries, and
the political instability of the two countries mentioned
gave some interviewees cause for concern. Domestic
firm-firm partnerships seemed to be very limited, with
international linkages, particularly to India, more preva-
lent. ‘I think there is some suspicion’ between firms, was
one interviewee’s interpretation.
Although technology transfer in Uganda is limited,
there are some interesting activities worthy of note. One
‘virtual incubatee’ from UIRI is a health biotechnology
enterprise called ASTEL. A local 8-10 person enterprise
established by a Ugandan entrepreneur, Vinand Nantu-
lya, ASTEL has just begun manufacturing diagnostic kits
for malaria, hepatitis B and pregnancy using lateral flow
technology. This technology is not novel globally but it
is new to the country, and extremely beneficial in situa-
tions where populations live far from test sites as lateral
flow diagnostic tests significantly reduce waiting time
for results. ASTEL has no local competitors in Uganda,
and is priced competitively compared to imports. Dr
Nantulya intends to start substituting raw materials for
locally-made ones, and thus, in time, to drive price
down further.
While significant novel R&D is not taking place within
firms in Uganda, it is the goal of a private biomedical
research institution, Med Biotech Labs, which was
started in 1995 by Dr Tom Egwang, a Ugandan micro-
biologist. The mission of Med Biotech is to undertake
research on diseases that affect the Ugandan population,
to build capacity in biotechnology and medical research
and to facilitate technology transfer. Med Biotech
engages in R&D, and preclinical and clinical trials of
medical and agricultural biotechnology. Under an MSI
competitive grant, Med Biotech won US$800,000 to pre-
pare infrastructure for malaria vaccine clinical trials set
to take place in Northern Uganda, and to fund capacity
building for these trials. This grant is the first major
funding Med Biotech has received from the Uganda
government. Other sources of funding for Med Biotech
include an NIH planning grant to build capacity for
malaria research, and European Union funds for colla-
boration with European institutes in malaria vaccine dis-
covery. This extensive funding support has enabled Med
Biotech to undertake innovative dual-purpose projects,
such as the malaria vaccine clinical trials in Northern
Uganda which our interviewee said are also intended to
draw resources to a very underdeveloped part of the
country.
The absence of early-stage finance and human
resources were reported as hindering innovation and
longer-term strategies. We found no evidence of venture
capital for health innovation during our study and iden-
tified only one instance of angel funding from private
sources. No interviewee asked could provide examples
of venture capital pools or other organized private
sources of early stage funding. Government support for
small enterprises is minimal in this respect. However, it
is encouraging that MSI money is beginning to be dis-
bursed towards more innovative health enterprises and
the element of competition among firms or NGOs may
be productive in generating novel ideas and flexible
business models. As in the public research institutes,
inadequate technical skills were also mentioned as a
constraint to private sector R&D. Though KPI has a lab
outfitted to conduct R&D, our interviews indicate that
insufficient human resources mean that the lab is used
for drug formulation only, and no R&D takes place
within the firm. To meet its human resource needs,
Med Biotech Labs has had to train its own personnel,
and does so by taking in PhD and Masters students and
giving them on-the-job training. This supports one
interviewee’s assertion that local human resources ‘can
be harnessed’ if enterprises are given support.
NGOs and donors
As indicated in earlier sections, foreign donors – such as
the Rockefeller Foundation, the World Bank and the
European Union - have been instrumental in almost all
of the innovation activities in Uganda, and as such
strongly influence the health innovation landscape. We
also identified two other donor-driven initiatives aimed
specifically at strengthening commercialization.
The first one, BIO-EARN, is a regional project funded
by the Swedish International Development Co-operation
Agency (SIDA) that aims at increasing research capacity
primarily in agricultural, environmental and industrial
biotechnology. The program is a regional one and
includes researchers from Kenya, Uganda, Tanzania and
Ethiopia. The BIO-EARN project also has a commercia-
lization component whose objective is to encourage lin-
kages between industry and research: in 2008 grants
were competitively awarded to six projects which relate
to environmental, industrial and agricultural biotechnol-
ogy to encourage developing their technologies into pro-
ducts with the help of industry [22]. A recent evaluation
of the project drew a number of lessons, including the
need to take into account both economic and social
demand for biosciences knowledge; the need for product
development funding to be included within grants,
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nated in a market or non-market context; and the need
to bring together wider expertise than only science
within biosciences research projects [22]. SIDA also
funds health research capacity building, and as of 2008
was funding 35 PhD students in the Makerere Univer-
sity College of Health Sciences on projects ranging from
reproductive health to molecular biology research [19].
The United States Agency for International Develop-
ment (USAID), through the Program for Biosafety Sys-
tems, supports the development of biotechnology and
biosafety policies. They have also funded the activities of
the Uganda Legal Reform Commission, established to
evaluate the changes needed to Uganda’s legal frame-
work to become TRIPS-compliant.
An interesting initiative by a domestic institution is
also playing a part in Uganda’s innovation system. In
September 2008, the Uganda National Academy of
Sciences (UNAS) started a pilot pairing scheme between
MPs who sit on the parliamentary science and technol-
ogy committee and Ugandan scientists. UNAS is a non-
governmental entity that provides a forum for the
advancement of science through discussion and debate.
Modeled on a similar UK pairing project, five Ugandan
scientists were matched with five Ugandan legislators.
The scientists spent a week in Parliament shadowing the
partner parliamentarian. Conversely, the parliamentar-
ians were to visit the scientists at their respective
research institutes. The project proved to be successful
in its objective of sensitizing each partner in the pairing,
and the project was seeking funding to scale up in 2009.
Conclusions
Strengths and good practices
Our case study highlighted several strengths which
Uganda could build upon to improve its health product
innovation system. Among them are: political will to
developing STI as shown by the government’si n v e s t -
ment in the MSI program and the Presidential Support
to Scientists Fund; the presence of health research in-
country particularly at Makerere University College of
Health Sciences, Med Biotech Labs and at the public
health research institutes; a pharmaceutical industry that
has started to create partnerships, particularly South-
South ones which encourage health product innovation
and are beginning to think of access to markets beyond
Uganda; and a traditional medicine research base parti-
cularly at the National Chemotherapeutics Labs which
has begun to explore the commercialization of Uganda’s
indigenous knowledge. A variety of support mechanisms
are also coming into existence to encourage innovation,
such as small-scale incubators, and public-private fora.
How these will be coordinated in the future is an impor-
tant question.
Unique to Uganda is the MSI Private Sector Coopera-
tion Fund (Window C Fund). Through our interviews
we learned that initial response to this initiative has
been slow: between 2007 and early 2009, the Council
received 45-50 proposals of which only four met the cri-
teria and quality required. UNCST staff attributed the
low response and poor quality of the proposals to a
number of reasons. Firstly, both academics and the pri-
vate sector are overly cautious, sometimes even suspi-
cious, when interacting with each other. Secondly, the
private sector tends to have a shorter term perspective
on the value of R&D to its profits than is needed for
health product development; it has therefore been reluc-
tant to invest time and money to cover what costs may
not be eligible under the grant into this collaboration.
Thirdly, it seemed that the private sector firms that did
get involved were not clear about their role within the
collaboration, which has led to weaker ownership from
the private sector partner. All the proposals that are
b e i n gf u n d e dw e r ep r e p a r e da n dl e db yt h ea c a d e m i c
partner in the collaboration, and therefore from
UNCST’s perspective Window C has not quite achieved
the intended degree of collaboration. In response to
these early lessons learned, UNCST and UIRI are work-
ing jointly to increase awareness in industry and engage
the private sector. UIRI is helping to disseminate infor-
mation and run workshops which include information
on how to develop good proposals. The two agencies
have also produced the MSI Window C Manual to
encourage and educate the private sector on its role and
the payoff in supporting R&D.
Despite its slow start, we consider the Window C
Fund an important, promising component of the inno-
vation process in Uganda. In addition to providing the
financial means for a concept to be tested, this Fund
encourages collaboration between firms and researchers
through the exploration of a real problem experienced
by industry. Such opportunities for collaboration in turn
increase awareness in researchers about commercializa-
tion and appreciation in the private sector for R&D.
Most importantly, as this fund is one of the few product
development funds currently in operation in sub-
Saharan Africa, the lessons learned in this case could be
built upon by other African countries seeking to imple-
ment this important component of the innovation
process.
Recommendations
Science-based health innovation is nascent in Uganda.
The political will to develop STI capacity, demonstrated
through initiatives such as the Presidential Support to
Scientists Fund, has made some progress in stimulating
commercialization. However, government leadership at
the policy level is needed to align the priorities and
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the nation’s priorities. This gap is evident in two areas.
Firstly, in the absence of a ministry responsible solely
for STI, key players in the Ugandan government are
scattered through a number of ministries. UNCST is
therefore limited in delivering on its mandate to coordi-
nate. From our study it is evident that this fragmenta-
tion reduces the ability of the different players to
coordinate science research towards commonly under-
stood national priorities, and sometimes the different
agencies created have parallel mandates which creates
friction amongst them. Secondly, even with strong poli-
tical support for STI, a major stumbling block is the
stagnation of Bills in the parliament or the cabinet as
they await debate and approval. Examples of policies
that are stuck include the STI policy (presented to Cabi-
net in 2006 and as of May 2009, has been passed in
Cabinet but not in Parliament), the Traditional Medi-
cines Bill (presented to Cabinet in 2000 but not yet
passed),and the Bill to enact UNHRO (presented to
Cabinet in 2001 and finally approved by Cabinet and
Parliament in 2009). While the existence of these draft
policies indicates definite awareness of the policies
needed to support STI, particularly health innovation,
the stagnation of the bills has slowed down the process
of strengthening the policy framework. Due to this gap
in government leadership, local health research priorities
are more often than not responsive to foreign organiza-
tions and not directed towards local industry needs and
demand.
A range of activities to support innovation have been
put in motion, such as the creation of incubator facil-
ities and tech transfer initiatives like the I@Mak pro-
gram, which demonstrates not only attention to the
impact of knowledge but a genuinely new institutional
approach to meeting economic and social demands at a
district level. In the private sector, there are examples of
incremental innovation to address neglected disease, dri-
ven by entrepreneurial individuals. What is needed is
linking the different innovation initiatives more
effectively.
Insufficient human resources, particularly in research
institutes and pharmaceutical firms, are an impediment
to health innovation. It was perceived by our intervie-
wees that not enough high quality scientists are graduat-
ing from the local university system, which in turn
means that research institutes do not have sufficient
research expertise. For example, only 40 pharmacists
graduate every year from the training programs. Firms
struggle with finding the industrial skills base they need.
Within government, lack of expertise in R&D regulation
has also slowed down some innovation initiatives.
Our study found some linkages exist between
research, the private sector and government to enable
development of novel health solutions and products,
and that limited interactions between the different
groups do take place. Among other examples, UIRI net-
works with universities and the MUPSF supports pri-
vate-public collaboration. However, these linkages are
not yet leading to increased and efficient knowledge
flows between industry and research that support
commercialization.
Recommendation 1: Create a Ministry of Science,
Technology and Innovation. The creation of a Ministry
of Science, Technology and Innovation was suggested by
interviewees in our study, as well as in a number of
research studies on Uganda and in commentaries in
local newspapers. Many see this Ministry as a critical
missing piece for improving innovation in Uganda, and
the latest version of the STI policy does includes the
creation of this Ministry as a part of the implementa-
tion. The Ugandan government also needs to expedite
the parliamentary process of approving policies to
enable the implementation of this recommendation. To
alleviate this delay, initiatives such as the parliamentar-
ian-scientist pairing piloted by the Uganda National
Academy of Sciences in 2008 can be scaled up to
include and sensitize more parliamentarians. In the UK,
a similar initiative has resulted in a greater understand-
ing by parliamentarians of the need for the specific poli-
cies that support STI. A similar outcome is possible in
Uganda.
Recommendation 2: Support human resource develop-
ment in health innovation by capitalizing on and sup-
porting existing skills training and transfer programs.
Some initiatives to increase training are already in place,
and indicate how meeting the human resource gap in
research institutes and in firms could be achieved. MSI’s
Window C provides an opportunity for a demand-driven
training process where training is done to meet industry
demand. In the private sector firms, programs exist to
train university students in pharmaceuticals through
internships and to provide hands-on industrial training.
These demand-driven training programs ensures that
university graduates are trained in skills currently
needed in industry, thus reducing the skills gap more
effectively. Such initiatives should be sustained and
scaled up, in addition to paying attention to the more
traditional training at universities.
Recommendation 3: Monitor, evaluate, and dissemi-
nate lessons from innovative initiatives by creating
means to identify and understand their successes and
challenges. These initiatives need to be monitored and
coordinated in order to learn lessons that are specific
to the Ugandan context. Opportunities to learn lessons
on how to support Ugandan health innovation and to
build on their pioneering efforts are currently being
missed. Such monitoring and evaluation processes
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duplicated.
Recommendation 4: Create a mechanism to enhance
knowledge translation and linkages between business,
science and capital providers in the health area. Plat-
forms such as MUPSF indicate nascent linkage mechan-
isms exist in Uganda, but they need to work within a
larger context of knowledge flows between research and
industry with the specific aim of commercialization and
a focus on clear health targets. Uganda could capitalize
on these existing methods as a starting point for build-
ing partnerships that could lead to collaboration. In
addition, as noted in our previous work, life sciences
innovation centers are another mechanism for focusing
linkages around innovation and product development
[23-25]. Developing this mechanism could facilitate
funding flows, particularly from foreign sources. Scaling
up of funding support for commercialization like the
MSI program and the Presidential Support to Scientists
Fund would encourage more technologies to move out
of the labs and into the marketplace. Given the
restricted domestic capital options in Uganda, stronger
linkages with foreign sources could potentially bring in
“patient capital” that might offer funds for R&D in
exchange for a reasonable financial return.
Uganda, because of its history of high quality health
research at Makerere University and other research
institutes, has a sound basis for going to the next level:
to capture more of the value of its research and, work-
ing with the private sector and other partners, to focus
on health product development and translation of
research into applied solutions.
Science-based health product innovation is in its early
stages in Uganda, as are policies for guiding its develop-
ment. Nevertheless, Uganda has recently been at the
forefront of interesting new approaches to S&T develop-
ment, particularly with respect to generating innovation
and local value from research in a variety of ways.
Experience from other countries and contexts has
demonstrated how technological innovation requires
institutional innovation – Uganda’sa c t i v i t i e st os u p p o r t
technology transfer and private-public collaboration
need to be monitored, coordinated, and learned from
over coming years, so that it and other countries in
Africa can make health and biomedical knowledge work
for them.
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